<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>29180129</identifier>
<setSpec>1578-2190</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Trujillo-Tiebas, M J</dc:author>
<dc:author>Escámez, M J</dc:author>
<dc:author>Sánchez-Jimeno, C</dc:author>
<dc:author>Ayuso, C</dc:author>
<dc:author>Del Río, M</dc:author>
<dc:description xml:lang="en">Epidermolysis bullosa (EB) is a rare genetic disease that causes mucocutaneous fragility. It comprises a clinically and genetically heterogeneous group of disorder characterized by spontaneous or contact/friction-induced blistering. EB is classified into 4 types-simplex, junctional, dystrophic, and Kindler syndrome-and 30 subtypes. The disease is caused by defects in proteins implicated in dermal-epidermal adhesion. At least 19 genes have been characterized and more than 1000 mutations identified, thus rendering diagnosis complex. Molecular diagnosis of EB is the last stage of a laborious process that starts with a detailed clinical history compilation and careful procurement of a skin fresh biopsy that includes an area where the epidermis detaches from the dermis. The detachment area makes it possible to establish the cleavage plane by antigen mapping and, in the best scenario, to identify a single candidate gene to search for pathogenic mutations. The results of the molecular diagnosis enable the physician to provide appropriate genetic counseling (inheritance pattern, risk of recurrence, and options for prenatal and preimplantation diagnosis) and implement subsequent preventive programs, as well as to establish a reasonable clinical prognosis facilitating access to specific therapy and rehabilitation. Lastly, molecular diagnosis is essential for the participation of patients in clinical trials, a critical issue given the current incurable status of EB. The present guidelines aim to disseminate the procedure for diagnosing EB in our laboratory and thus avoid suboptimal or incomplete clinical diagnoses. The recommendations we provide are the result of more than 10 years' experience in the molecular diagnosis of EB in Spain.</dc:description>
<dc:type>Journal Article</dc:type>
<dc:language>es</dc:language>
<dc:subject>Diagnóstico prenatal</dc:subject>
<dc:subject>Diagnóstico genético</dc:subject>
<dc:subject>Epidermolysis bullosa</dc:subject>
<dc:subject>Kindler syndrome</dc:subject>
<dc:subject>Epidermolysis bullosa junctional</dc:subject>
<dc:subject>Antigen mapping</dc:subject>
<dc:subject>Epidermólisis bullosa juntural</dc:subject>
<dc:subject>Epidermolysis bullosa simplex</dc:subject>
<dc:subject>Síndrome de Kindler</dc:subject>
<dc:subject>Diagnóstico preimplantacional</dc:subject>
<dc:subject>Epidermólisis bullosa distrófica</dc:subject>
<dc:subject>Genetic diagnosis</dc:subject>
<dc:subject>Epidermolysis bullosa dystrophic</dc:subject>
<dc:subject>Genodermatosis</dc:subject>
<dc:subject>Preimplantation diagnosis</dc:subject>
<dc:subject>Epidermólisis bullosa</dc:subject>
<dc:subject>Epidermólisis bullosa simple</dc:subject>
<dc:subject>Mapeo antigénico</dc:subject>
<dc:subject>Prenatal diagnosis</dc:subject>
<dc:date>2017 Nov 24 </dc:date>
<dc:title xml:lang="es">Diagnóstico genético de la epidermólisis bullosa: recomendaciones de un grupo español de expertos.</dc:title>
<dc:title xml:lang="en">Genetic diagnosis of epidermolysis bullosa: recommendations from an expert Spanish research group.</dc:title>
<dc:publisher>Actas dermo-sifiliograficas</dc:publisher>
</metadata>
</record>
</pubmed-document>
